- Conditions
- Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage IA Breast Cancer AJCC v8, Anatomic Stage IB Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage IIA Breast Cancer AJCC v8, Anatomic Stage IIB Breast Cancer AJCC v8, Anatomic Stage IIIA Breast Cancer AJCC v8, HER2 Negative Breast Adenocarcinoma, Hormone Receptor Positive Breast Adenocarcinoma, Invasive Breast Carcinoma, Multifocal Breast Carcinoma, Prognostic Stage I Breast Cancer AJCC v8, Prognostic Stage IA Breast Cancer AJCC v8, Prognostic Stage IB Breast Cancer AJCC v8, Prognostic Stage II Breast Cancer AJCC v8, Prognostic Stage IIA Breast Cancer AJCC v8, Prognostic Stage IIB Breast Cancer AJCC v8, Prognostic Stage IIIA Breast Cancer AJCC v8, Prognostic Stage IIIB Breast Cancer AJCC v8, Unilateral Breast Carcinoma
- Interventions
- Abemaciclib, Niraparib Tosylate Monohydrate
- Drug
- Lead sponsor
- OHSU Knight Cancer Institute
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 8 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2025
- U.S. locations
- 1
- States / cities
- Portland, Oregon
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 313–336
of 710
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Postsurgical Pain
- Interventions
- AYX1 Injection 660 mg / 6 mL, AYX1 Injection 1100 mg / 10 mL, Placebo Injection 6 mL, Placebo Injection 10 mL
- Drug
- Lead sponsor
- Adynxx, Inc.
- Industry
- Eligibility
- 40 Years to 80 Years
- Enrollment
- 120 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2015
- U.S. locations
- 2
- States / cities
- Sheffield, Alabama • Phoenix, Arizona
- Conditions
- Stage IIA Breast Cancer, Stage IIB Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer, Stage IV Breast Cancer
- Interventions
- Cyclophosphamide, Cytology Specimen Collection Procedure, Doxorubicin Hydrochloride, Laboratory Biomarker Analysis, Paclitaxel, Trastuzumab, Endocrine therapy
- Drug · Other · Biological
- Lead sponsor
- Albert Einstein College of Medicine
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 31 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2023
- U.S. locations
- 1
- States / cities
- The Bronx, New York
- Conditions
- Glioblastoma, Malignant Glioma, Recurrent Glioblastoma, Recurrent Malignant Glioma, Recurrent Grade III Glioma, Grade III Glioma
- Interventions
- Nivolumab, Quality-of-Life Assessment, Questionnaire Administration
- Biological · Other
- Lead sponsor
- Sabine Mueller, MD, PhD
- Other
- Eligibility
- 6 Months to 25 Years
- Enrollment
- 9 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2028
- U.S. locations
- 14
- States / cities
- Birmingham, Alabama • Los Angeles, California • San Diego, California + 11 more
- Conditions
- Pelvic Organ Prolapse
- Interventions
- Mechanical Bowel Prep, No Mechanical Bowel Prep
- Other
- Lead sponsor
- Boston Urogynecology Associates
- Other
- Eligibility
- 18 Years to 90 Years · Female only
- Enrollment
- 176 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2017
- U.S. locations
- 1
- States / cities
- Cambridge, Massachusetts
- Conditions
- Obesity
- Interventions
- LEARN group
- Behavioral
- Lead sponsor
- Mayo Clinic
- Other
- Eligibility
- 25 Years to 65 Years
- Enrollment
- 34 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2012
- U.S. locations
- 1
- States / cities
- Rochester, Minnesota
- Conditions
- Thyroid Gland Anaplastic Carcinoma, Thyroid Gland Squamous Cell Carcinoma
- Interventions
- Conventional Surgery, Dabrafenib, Intensity-Modulated Radiation Therapy, Pembrolizumab, Quality-of-Life Assessment, Trametinib
- Procedure · Drug · Radiation + 2 more
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2028
- U.S. locations
- 6
- States / cities
- Stanford, California • Ann Arbor, Michigan • Rochester, Minnesota + 3 more
- Conditions
- Hydronephrosis, Infiltrating Bladder Urothelial Carcinoma Sarcomatoid Variant, Infiltrating Bladder Urothelial Carcinoma, Micropapillary Variant, Infiltrating Bladder Urothelial Carcinoma, Plasmacytoid Variant, Infiltrating Renal Pelvis Urothelial Carcinoma, Sarcomatoid Variant, Renal Pelvis Urothelial Carcinoma, Stage II Bladder Urothelial Carcinoma AJCC v6 and v7, Stage II Renal Pelvis Cancer AJCC v7, Stage II Ureter Cancer AJCC v7, Stage II Urethral Cancer AJCC v7, Stage III Bladder Urothelial Carcinoma AJCC v6 and v7, Stage III Renal Pelvis Cancer AJCC v7, Stage III Ureter Cancer AJCC v7, Stage III Urethral Cancer AJCC v7, Stage IV Renal Pelvis Cancer AJCC v7, Stage IV Ureter Cancer AJCC v7, Stage IV Urethral Cancer AJCC v7, Ureter Urothelial Carcinoma, Urethral Urothelial Carcinoma
- Interventions
- Durvalumab, Therapeutic Conventional Surgery, Tremelimumab
- Biological · Procedure
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 54 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2027
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- ATM Gene Mutation, BRCA1 Gene Mutation, BRCA2 Gene Mutation, BRIP1 Gene Mutation, CDK12 Gene Mutation, CHEK1 Gene Mutation, CHEK2 Gene Mutation, DNA Damage Response Gene Mutation, DNA Repair Gene Mutation, FANCA Gene Mutation, FANCD2 Gene Mutation, FANCL Gene Mutation, GEN1 Gene Mutation, NBN Gene Mutation, Prostate Carcinoma, RAD51 Gene Mutation, RAD51C Gene Mutation
- Interventions
- Niraparib, Niraparib Tosylate Monohydrate, Radical Prostatectomy
- Drug · Procedure
- Lead sponsor
- University of California, Davis
- Other
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 11 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2025
- U.S. locations
- 1
- States / cities
- Sacramento, California
- Conditions
- Breast Neoplasms
- Interventions
- Low carbohydrate diet, Low fat diet
- Behavioral
- Lead sponsor
- Albert Einstein College of Medicine
- Other
- Eligibility
- 21 Years and older · Female only
- Enrollment
- 11 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2020
- U.S. locations
- 1
- States / cities
- The Bronx, New York
- Conditions
- Recurrent Renal Cell Carcinoma, Stage I Renal Cell Cancer, Stage II Renal Cell Cancer
- Interventions
- Laboratory Biomarker Analysis, Nephrectomy, Renal Cell Carcinoma/CD40L RNA-Transfected Autologous Dendritic Cell Vaccine AGS-003
- Other · Procedure · Biological
- Lead sponsor
- Roswell Park Cancer Institute
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 5 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2017
- U.S. locations
- 1
- States / cities
- Buffalo, New York
- Conditions
- Patients Undergoing Elective Coronary Artery Bypass Graft
- Interventions
- Lansoprazole
- Drug
- Lead sponsor
- Temple University
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2006
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Opioid Use
- Interventions
- Educational materials
- Other
- Lead sponsor
- Brendan M. Patterson
- Other
- Eligibility
- 21 Years to 99 Years
- Enrollment
- 140 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2022 – 2024
- U.S. locations
- 1
- States / cities
- Iowa City, Iowa
- Conditions
- Clinical Stage I Cutaneous Melanoma AJCC v8, Clinical Stage IA Cutaneous Melanoma AJCC v8, Clinical Stage IB Cutaneous Melanoma AJCC v8, Clinical Stage II Cutaneous Melanoma AJCC v8, Clinical Stage IIA Cutaneous Melanoma AJCC v8, Clinical Stage IIB Cutaneous Melanoma AJCC v8, Clinical Stage IIC Cutaneous Melanoma AJCC v8, Pathologic Stage I Cutaneous Melanoma AJCC v8, Pathologic Stage IA Cutaneous Melanoma AJCC v8, Pathologic Stage IB Cutaneous Melanoma AJCC v8, Pathologic Stage II Cutaneous Melanoma AJCC v8, Pathologic Stage IIA Cutaneous Melanoma AJCC v8, Pathologic Stage IIB Cutaneous Melanoma AJCC v8, Pathologic Stage IIC Cutaneous Melanoma AJCC v8
- Interventions
- Cefazolin, Resection
- Drug · Procedure
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2027
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Locally Advanced Rectal Adenocarcinoma, Metastatic Rectal Adenocarcinoma, Rectal Adenocarcinoma, Stage III Rectal Cancer AJCC v7, Stage IIIA Rectal Cancer AJCC v7, Stage IIIB Rectal Cancer AJCC v7, Stage IIIC Rectal Cancer AJCC v7, Stage IV Rectal Cancer AJCC v7, Stage IVA Rectal Cancer AJCC v7, Stage IVB Rectal Cancer AJCC v7
- Interventions
- Capecitabine, Fluorouracil, Leucovorin, Oxaliplatin, Radiation Therapy, Talimogene Laherparepvec
- Drug · Radiation · Biological
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 3 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2022
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Cancer
- Interventions
- Structured perioperative nutrition and exercise, Nutrition and Exercise Counseling
- Behavioral
- Lead sponsor
- VA Office of Research and Development
- Federal
- Eligibility
- 55 Years and older
- Enrollment
- 188 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2027
- U.S. locations
- 1
- States / cities
- Durham, North Carolina
- Conditions
- Postsurgical Pain
- Interventions
- Placebo Injection, AYX1 Injection 110 mg, AYX1 Injection 330 mg
- Drug
- Lead sponsor
- Adynxx, Inc.
- Industry
- Eligibility
- 40 Years to 80 Years
- Enrollment
- 102 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013
- U.S. locations
- 7
- States / cities
- Sheffield, Alabama • Phoenix, Arizona • Boynton Beach, Florida + 4 more
- Conditions
- Locally Advanced Cutaneous Squamous Cell Carcinoma of the Head and Neck, Resectable Cutaneous Squamous Cell Carcinoma of the Head and Neck, Stage III Cutaneous Squamous Cell Carcinoma of the Head and Neck AJCC v8
- Interventions
- Atezolizumab, Radiation Therapy, Therapeutic Conventional Surgery
- Biological · Radiation · Procedure
- Lead sponsor
- University of California, Davis
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 1 participant
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2023
- U.S. locations
- 1
- States / cities
- Sacramento, California
- Conditions
- Adrenal Insufficiency Neonatal
- Interventions
- No pre-operative steroids
- Other
- Lead sponsor
- University of Alabama at Birmingham
- Other
- Eligibility
- 1 Day to 60 Days
- Enrollment
- 50 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2019
- U.S. locations
- 1
- States / cities
- Birmingham, Alabama
- Conditions
- Brain Mass, Glioma
- Interventions
- Functional Magnetic Resonance Imaging, Magnetic Resonance Imaging, Resting State Functional Connectivity Magnetic Resonance Imaging
- Procedure
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 29 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2024
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Perioperative Bleeding
- Interventions
- Not listed
- Lead sponsor
- Cedars-Sinai Medical Center
- Other
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2009
- U.S. locations
- 1
- States / cities
- Los Angeles, California
- Conditions
- Colorectal Cancer
- Interventions
- capecitabine, conventional surgery, neoadjuvant therapy, radiation therapy
- Drug · Procedure · Radiation
- Lead sponsor
- Fox Chase Cancer Center
- Other
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2003 – 2007
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Corneal Epithelium Defect
- Interventions
- 0.3% hypromellose
- Drug
- Lead sponsor
- Augusta University
- Other
- Eligibility
- 18 Years to 60 Years
- Enrollment
- 80 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2007 – 2009
- U.S. locations
- 1
- States / cities
- Augusta, Georgia
- Conditions
- Surgery, Immune System and Related Disorders, Preoperative Care, Gastrointestinal Disease, Urological Disease, Gynecologic Disease, Thoracic Diseases
- Interventions
- Physical Prehabilitation, Stress Reduction Prehabilitation, Cognitive Prehabilitation, Nutrition Prehabilitation
- Behavioral
- Lead sponsor
- Stanford University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 55 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2024
- U.S. locations
- 1
- States / cities
- Stanford, California